0
Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
0 Vote
1 Contributor
1421 Views 
0 Saved
0 Vote 1 Contributor1421 Views 0 SavedYou might also be interested in
No, not every cancer patient needs chemotherapy. Treatment depends on the type and stage of cancer. Some may need surgery, radiation, or newer therapies like immunotherapy. Your doctor will recommend the best plan for your condition. I’m scared chemotherapy will make me lose my hair. Is there any....
Hello, please describe your problem in detail, then only we'll be able to provide you treatment costs. You can call us on +91-8010994994 and talk to our medical expert.
A new treatment for breast cancer has completely eradicated tumours in just 11 days. A team of researchers in the UK claims the new two-pronged technique could spare thousands of women from gruelling chemotherapy. Doctors combined two existing cancer drugs - Tyverb and Herceptin – and gave them t....
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.